nafamostat has been researched along with Biliary Tract Neoplasms in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Biliary Tract Neoplasms: Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Biliary cancer and pancreatic cancer are considered to be difficult diseases to cure." | 2.52 | Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. ( Uwagawa, T; Yanaga, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uwagawa, T | 1 |
| Yanaga, K | 1 |
1 review available for nafamostat and Biliary Tract Neoplasms
| Article | Year |
|---|---|
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; C | 2015 |